This "Algo Med" share price could go BONKERS!

It's the kind of return that could literally transform your life It's the kind of return that could literally transform your life                                                                                                      Wealth Daily: Fortune Favors the Bold   [Wealth Daily Logo 600x200 New]    by keith kohl / january 2, 2024 This "Algo Med" share price could go BONKERS! There's been a tremendous wave of hype around artificial intelligence (AI) in the stock market lately thanks to ChatGPT. A lot of it is pure hype. However, the opportunity I'm discussing today isn't about jumping on the AI bandwagon. Long before ChatGPT became a household name, an AI tool was already making waves in the realm of pharmaceutical research. The small firm leading the charge with this tool just achieved something extraordinary... It has brought forth the first-ever drug created by AI to enter human clinical trials. But that’s just the start. This company has even more AI-generated drugs in its clinical trial pipeline... With at least one of them already on the verge of FDA approval! It's no surprise that Morgan Stanley sees AI drug development becoming a $50 billion market... And this company’s breakthrough could become the first AI drug in history. Once it gets approved, this firm’s share price is poised to skyrocket like never before. [Don't delay — find out more while the opportunity lasts.]( To your wealth, [Keith's sign off] Keith Kohl Investment Director, Topline Trader P.S. AI has caused a major stir in the stock market, but I'm not here to join the hype train... Because even before ChatGPT was a buzzword, a small firm was already revolutionizing pharma research using AI. It’s made history with the first AI-developed drug to enter human trials. More such drugs are in its pipeline, with one nearing FDA approval! As the AI drug development market is estimated to hit the $50 billion mark, this company's shares are bound to take a massive leap. [Get the full scoop here.]( [Feedback? get in touch](mailto:/newsletter@wealthdaily.com?subject=Wealth%20Daily%20feedback) [Read this email online]( [Manage Newsletters]( [Share on Twitter]( You signed up for our newsletter with the email {EMAIL}. You can manage your subscription and get our privacy policy [here](. This email is from Angel Publishing, 3 East Read Street, Baltimore, MD 21202 © Wealth Daily.